ENV-101, A Novel Hedgehog Inhibitor, Increases Lung Function, and Reduces Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (ATS 2024) - Mar 17, 2024 - Pres time: May 19, 2024; 10:51 AM - 11:03 AM; Location: San Diego Convention Center, Room 8 (Upper Level); P2 | " ENV-IPF-101 (NCT04968574) was a randomized, double-blind, placebo (PBO)-controlled trial of ENV-101, a novel Hh pathway inhibitor (Hhi), in patients with IPF conducted at 16 clinical sites in Australia, Canada, South Korea, Malaysia, and Mexico... These results suggest that ENV-101 improves IPF by reducing lung fibrosis and increasing lung volume, which translates into improved lung function in patients with IPF within 12 weeks. These results support the Phase 2b trial planned in IPF and PF-ILD."
Clinical • Late-breaking abstract • P2 data • Alopecia • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
T. M. Maher1; J. G. Goldin2; A. DiFrancesco3; M. de los Rios3; C. Quito3; S. Kim3; P. A. Frohna4; J. Hood3
|